. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91探花

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91探花

Skip to main content
Home
About us
News
91探花 launches new wild type cell product ioMicroglia

14.06.2023 | Published by 91探花

91探花 launches new wild type cell product ioMicroglia

Featured Image

Today 91探花 has launched the first immune cell product in its ioCells鈩� wild type portfolio: ioMicrogliaTM. The product will enable reliable neuroinflammation research and therapeutics development for neurodegenerative diseases. With the collation of datasets from multiple independent labs 91探花 has closed the ioMicroglia Early Access Program.

These human iPSC-derived ioMicroglia have been independently verified by external experts in academia and industry, including Charles River Laboratories and the Medicines Discovery Catapult as part of our Early Access Program. Our testers have verified that in just 10 days, they can start running consistent, disease-relevant functional assays supporting their drug discovery workflows and disease research.

What does the new data show? 

  • Multiple independent labs have generated cytokine secretion data that shows ioMicroglia exhibit a pro-inflammatory response to LPS, which can be inhibited with dexamethasone, and amyloid beta which is of relevance for Alzheimer's disease research.
  • There is fresh Bulk RNA sequencing data showing highly consistent gene expression between independently manufactured lots, so you can eliminate assay variability.
  • We have more phagocytosis data, demonstrating phagocytosis of amyloid beta-42 particles and E. coli particles, showing consistent disease-relevant functionality across manufactured lots. At ISSCR, additional new data from Early Access Testers is being presented, highlighting the experimental reproducibility of ioMicroglia in phagocytosis assays.

ioMicroglia d6 40min recording colour

ioMicroglia morphology at day 6 post-thaw.

ioMicroglia are precision reprogrammed from human iPSCs using opti-oxTM technology, meaning they are ready for experiments in 10 days and have consistency built-in, always expressing the same key markers regardless of lot or vial. In addition, each lot of ioMicroglia is functional as QC analysis includes phagocytosis and cytokine secretion assays. 

With these key features, ioMicroglia enable scientists to overcome long complex protocols, inconsistent cell populations and lot variability commonly associated with classical directed differentiation methods used to generate iPSC-derived microglia.

Therefore, with ioMicroglia, scientists can accelerate and improve the reliability and reproducibility of their experiments.

"We are excited to launch ioMicroglia with brand new phagocytosis, cytokine secretion and bulk RNA sequencing data, marking the close of the Early Access Program! This external data from multiple independent labs, in addition to our internal data, highlights the experimental reproducibility of ioMicroglia in terms of disease-relevant functional assays. New internal bulk RNA sequencing data demonstrates that ioMicroglia show highly consistent gene expression between independently manufactured lots, offering scientists improved experimental reliability."

Malathi Raman
Malathi RamanSenior Product Manager, 91探花

This launch expands 91探花's ioCells portfolio to immune cells and expands its existing portfolio for the central nervous system. Learn more.

Related pages

About us Coding cells to advance the wellbeing of humanity
Careers See the latest openings
Blog See the latest blogs